

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
22 December 2022 (22.12.2022)



(10) International Publication Number
WO 2022/266396 A1

(51) International Patent Classification:

A61K 35/17 (2015.01) C12N 15/11 (2006.01)
C12N 5/078 (2010.01) C12N 15/12 (2006.01)
C07K 19/00 (2006.01) C12N 15/85 (2006.01)
C12N 5/10 (2006.01)

(21) International Application Number:

PCT/US2022/033893

(22) International Filing Date:

16 June 2022 (16.06.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/211,468 16 June 2021 (16.06.2021) US
63/305,155 31 January 2022 (31.01.2022) US

(71) Applicant: **SENTI BIOSCIENCES, INC.** [US/US]: 2
Corporate Drive, First Floor, South San Francisco, California
94080 (US).

(72) Inventors: **GUZMAN AYALA, Marcela**; c/o SENTI
BIOSCIENCES, INC., 2 Corporate Drive, First Floor,
South San Francisco, California 94080 (US). **GORDLEY,
Russell Morrison**; c/o SENTI BIOSCIENCES, INC., 2
Corporate Drive, First Floor, South San Francisco, California
94080 (US). **HUNG, Michelle Elizabeth**; c/o SENTI
BIOSCIENCES, INC., 2 Corporate Drive, First Floor,
South San Francisco, California 94080 (US). **LEE, Gary**;
c/o SENTI BIOSCIENCES, INC., 2 Corporate Drive, First
Floor, South San Francisco, California 94080 (US). **LU,
Timothy Kuan-Ta**; c/o SENTI BIOSCIENCES, INC., 2
Corporate Drive, First Floor, South San Francisco, California
94080 (US).

(74) Agent: **NEWMAN, Zachary R.** et al.; Goodwin Procter
LLP, 100 Northern Avenue, IP DOCKETING DEPT./7TH
FL, Boston, Massachusetts 02210 (US).

(81) Designated States (*unless otherwise indicated, for every
kind of national protection available*): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,

CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH,
KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA,
MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI,
NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU,
RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM,
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM,
ZW.

(84) Designated States (*unless otherwise indicated, for every
kind of regional protection available*): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a
patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the
earlier application (Rule 4.17(iii))

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments (Rule 48.2(h))

(54) Title: ARMED CHIMERIC RECEPTORS AND METHODS OF USE THEREOF




FIG. 11

(57) Abstract: Described herein are immunoresponsive cells engineered to express cytokines, chimeric receptors, and synthetic transcription factor systems. Also described herein are nucleic acids, cells, and methods directed to the same.

WO 2022/266396 A1